Variables | N | Progression free survival (months) | P | |
---|---|---|---|---|
Median ± SE | 95% CI | |||
CypA | <0.01 | |||
Low | 16 | 16.42 ± 1.16 | 17.08-21.76 | |
High | 54 | 7.42 ± 0.60 | 6.24-8.59 | |
MMP9 | <0.01 | |||
Low | 20 | 16.332 ± 1.75 | 10.91-14.93 | |
High | 50 | 7.70 ± 0.62 | 6.49-8.91 | |
Age | 0.220 | |||
<65 | 48 | 11.47 ± 1.22 | 9.08-13.87 | |
≥65 | 22 | 9.44 ± 1.23 | 7.03-11.84 | |
Gender | 0.950 | |||
Male | 45 | 10.82 ± 1.24 | 8.38-13.25 | |
Female | 25 | 11.30 ± 1.45 | 8.46-14.15 | |
Smoking | 0.269 | |||
Yes (>40 pack-years) | 51 | 10.06 ± 1.02 | 8.01-12.05 | |
No | 19 | 12.35 ± 1.82 | 8.79-15.92 | |
Drink | 0.406 | |||
Yes (>50 ml/day) | 39 | 11.28 ± 1.25 | 8.83-13.72 | |
No | 31 | 10.07 ± 11.32 | 7.48-12.66 | |
Differentiation | <0.01 | |||
Well + Moderate | 39 | 13.33 ± 1.28 | 10.82-15.84 | |
Poor | 31 | 7.07 ± 0.78 | 5.54-8.60 | |
TNM stage | 0.295 | |||
I–II | 22 | 12.02 ± 1.87 | 8.36-15.67 | |
III–IV | 48 | 10.20 ± 1.02 | 8.20-12.19 | |
Lymph node | 0.041 | |||
Metastasis | 38 | 8.79 ± 1.20 | 6.44-11.14 | |
No metastasis | 32 | 12.75 ± 1.20 | 10.40-15.10 |